CSL opens new A$900 million plasma fractionation plant

7 December 2022

Australian biotech CSL Limited (ASX: CSL) today unveiled the future of plasma manufacturing in Australia with the opening of its A$900 million ($608 million) plasma fractionation facility in Victoria, which the company claims is the largest of its kind in the Southern Hemisphere. This is part of a A$2 billion-plus capital investment program CSL currently has underway in Australia.

The new state-of-the-art facility in Broadmeadows allows CSL’s manufacturing site to process up to 9.2 million plasma equivalent litres per annum. This is a nine-fold increase on current capacity for the site and will help meet the increasing demand for plasma-based, life-saving therapies for patients around the world.

The investment ensures the Broadmeadows site continues to play an important role in the manufacture and supply of life-saving medicines into Australia and other key markets, as well as secures advanced manufacturing jobs in Australia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK